2025年9月29日，辉瑞旗下Metsera公司公布，其超长效GLP-1受体激动剂候选药物MET-097i在两项IIb期临床试验中取得积极结果，28周每周给药平均体重减轻高达14.1%，个别患者达26.5%，且未出现疗效平台期。此前，9月22日，辉瑞宣布以最高73亿美元总对价收购Metsera，采用“固定预付款+业绩里程碑付款”模式，预付款49亿美元，里程碑付款上限约24亿美元。此次收购是辉瑞在...
Source Link2025年9月29日，辉瑞旗下Metsera公司公布，其超长效GLP-1受体激动剂候选药物MET-097i在两项IIb期临床试验中取得积极结果，28周每周给药平均体重减轻高达14.1%，个别患者达26.5%，且未出现疗效平台期。此前，9月22日，辉瑞宣布以最高73亿美元总对价收购Metsera，采用“固定预付款+业绩里程碑付款”模式，预付款49亿美元，里程碑付款上限约24亿美元。此次收购是辉瑞在...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.